RayKnowChina Research Map
Shortlist0

RecruitingHepatocellular carcinomaPhase 2

Registered title, quoted from ClinicalTrials.gov

A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With Apatinib

An open trial on hepatocellular carcinoma, registered on ClinicalTrials.gov. Led by Mengchao Hepatobiliary Hospital of Fujian Medical University; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorMengchao Hepatobiliary Hospital of Fujian Medical University福建医科大学孟超肝胆医院FuzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06280105, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 5

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (5 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Histological or pathological confirmed intermediate or advanced hepatocellular carcinoma, or patients with cirrhosis who meet the clinical diagnostic criteria for hepatocellular carcinoma of the American Association for the Study of Liver Diseases (AASLD);

    Inclusion criterion 3

    Containing components such as fibrolamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma, and cholangiocarcinoma that have been previously confirmed by histology/cytology;

    Inclusion criterion 14

  3. ECOG PS score: 0\~1;

    Inclusion criterion 6

  4. Blood routine: Neutrophils≥1.5×109/L Platelet count ≥75×109/L Hemoglobin ≥ 90g/L; 2. Liver and kidney function: Serum creatinine (SCr) ≤ 1.5 times the upper limit of normal (ULN) or creatinine clearance ≥ 50 ml/min (Cockcroft-Gault formula); Total bilirubin (TBIL) ≤ 3 times the upper limit of normal (ULN); Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) level ≤ 10 times the upper limit of normal (ULN); urine protein < 2+; if urine protein ≥ 2+, 24-hour urine protein quantification shows that the protein must be ≤ 1g; 10. Normal coagulation function, no active bleeding or thrombosis disease

    Inclusion criterion 10

    International normalized ratio INR≤1.5×ULN;

    Inclusion criterion 11

    Partial thromboplastin time APTT≤1.5×ULN;

    Inclusion criterion 12

  5. At least 1 measurable lesion (RECIST1.1)

    Inclusion criterion 7

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; earlier treatment; other conditions the trial excludes; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06280105, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Sign a written informed consent form before enrollment;
  • Age >18 years old, both sex;
  • Histological or pathological confirmed intermediate or advanced hepatocellular carcinoma, or patients with cirrhosis who meet the clinical diagnostic criteria for hepatocellular carcinoma of the American Association for the Study of Liver Diseases (AASLD);
  • Have progressed on the combination treatment of camrelizumab and apatinib for HCC
  • Child-Pugh Class A;
  • ECOG PS score: 0\~1;
  • At least 1 measurable lesion (RECIST1.1)
  • Expected survival period≥12 weeks
  • The function of vital organs meets the following requirements (excluding the use of any blood components and cell growth factors within 14 days):
  • Blood routine: Neutrophils≥1.5×109/L Platelet count ≥75×109/L Hemoglobin ≥ 90g/L; 2. Liver and kidney function: Serum creatinine (SCr) ≤ 1.5 times the upper limit of normal (ULN) or creatinine clearance ≥ 50 ml/min (Cockcroft-Gault formula); Total bilirubin (TBIL) ≤ 3 times the upper limit of normal (ULN); Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) level ≤ 10 times the upper limit of normal (ULN); urine protein < 2+; if urine protein ≥ 2+, 24-hour urine protein quantification shows that the protein must be ≤ 1g; 10. Normal coagulation function, no active bleeding or thrombosis disease
  • International normalized ratio INR≤1.5×ULN;
  • Partial thromboplastin time APTT≤1.5×ULN;
  • Prothrombin time PT≤1.5×ULN; 11. Non-surgical sterilization or female patients of childbearing age 12. Subjects voluntarily join this study, have good compliance, and cooperate with safety and survival follow-up

Main Exclusion Criteria:

  • Containing components such as fibrolamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma, and cholangiocarcinoma that have been previously confirmed by histology/cytology;
  • Have a history of hepatic encephalopathy;
  • Have a history of liver transplantation;
  • There is clinically significant pericardial effusion, and there are clinical symptoms of pleural effusion that require drainage;
  • Clinically apparent ascites is defined as meeting the following criteria: ascites can be detected by physical examination during screening or ascites needs to be drained during screening;
  • Simultaneous infection with HBV and HCV (having a history of HCV infection but negative HCV RNA can be considered as not being infected with HCV);
  • Presence of central nervous system metastasis or meningeal metastasis
  • Bleeding from esophageal or gastric varices caused by portal hypertension has occurred within 6 months before the first dose
  • Patients with any bleeding or bleeding event ≥CTCAE grade 3 within 4 weeks before the first dose
  • Arterial and venous thromboembolic events occurred within 6 months before the first dose
  • Uncontrolled high blood pressure
  • Symptomatic congestive heart failure
  • Severe bleeding tendency or coagulation disorder
  • Have a history of gastrointestinal perforation and/or fistula, intestinal obstruction within 6 months before the first dose
  • Active autoimmune disease or a history of autoimmune disease
  • Patients with HIV
  • According to the investigator's judgment, patients with other serious concomitant diseases that endanger the patient's safety or affect the patient's completion of the study.

Quoted from ClinicalTrials.gov, NCT06280105, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06280105, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06280105